 | • レポートコード：MRC2303B050 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界のリアルワールドエビデンス（RWE）ソリューション市場規模が予測期間中に年平均12.5％上昇すると推測されています。本調査書では、リアルワールドエビデンス（RWE）ソリューションの世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、コンポーネント別（請求データ、臨床設定データ、患者強化型データ、薬局データ、その他）分析、治療分野別（腫瘍、免疫学、神経内科、心血管系疾患、その他）分析、エンドユーザー別（医療保険者、医療従事者、製薬・医療機器企業、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Clinigen Group PLC、Icon PLC、IBM、IQVIA、Oracle Corporation、Parexel International、PerkinElmer Inc.、Pharmaceutical Product Development (PPD Inc.)、SAS Institute、Syneos Health、Flatiron Health Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のリアルワールドエビデンス（RWE）ソリューション市場規模：コンポーネント別 - 請求データにおける市場規模 - 臨床設定データにおける市場規模 - 患者強化型データにおける市場規模 - 薬局データにおける市場規模 - その他コンポーネントにおける市場規模 ・世界のリアルワールドエビデンス（RWE）ソリューション市場規模：治療分野別 - 腫瘍における市場規模 - 免疫学における市場規模 - 神経内科における市場規模 - 心血管系疾患における市場規模 - その他治療における市場規模 ・世界のリアルワールドエビデンス（RWE）ソリューション市場規模：エンドユーザー別 - 医療保険者における市場規模 - 医療従事者における市場規模 - 製薬・医療機器企業における市場規模 - その他エンドユーザーにおける市場規模 ・世界のリアルワールドエビデンス（RWE）ソリューション市場規模：地域別 - 北米のリアルワールドエビデンス（RWE）ソリューション市場規模 アメリカのリアルワールドエビデンス（RWE）ソリューション市場規模 カナダのリアルワールドエビデンス（RWE）ソリューション市場規模 メキシコのリアルワールドエビデンス（RWE）ソリューション市場規模 … - ヨーロッパのリアルワールドエビデンス（RWE）ソリューション市場規模 ドイツのリアルワールドエビデンス（RWE）ソリューション市場規模 イギリスのリアルワールドエビデンス（RWE）ソリューション市場規模 フランスのリアルワールドエビデンス（RWE）ソリューション市場規模 … - アジア太平洋のリアルワールドエビデンス（RWE）ソリューション市場規模 中国のリアルワールドエビデンス（RWE）ソリューション市場規模 日本のリアルワールドエビデンス（RWE）ソリューション市場規模 インドのリアルワールドエビデンス（RWE）ソリューション市場規模 … - 南米/中東のリアルワールドエビデンス（RWE）ソリューション市場規模 南アフリカのリアルワールドエビデンス（RWE）ソリューション市場規模 ブラジルのリアルワールドエビデンス（RWE）ソリューション市場規模 アルゼンチンのリアルワールドエビデンス（RWE）ソリューション市場規模 … ・競争状況 ・市場機会・将来動向 |
The real-world evidence solutions market is expected to register a CAGR of 12.5% during the forecast period.
The contagious coronavirus has a potential economic impact and implications on most sectors, including the pharmaceutical industry. Governments worldwide are now responding to the threat of COVID-19 with all the essential measures, such as social distancing, nationwide lockdown, travel restrictions, and large-scale quarantines that are anticipated to negatively impact businesses and consumer spending.
In the context of the COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on the development of effective and rapid diagnostic technologies. Moreover, many healthcare providers and drug developers have been stretching their available resources to curb the spread and develop effective medicines/vaccines for the COVID-19 pandemic. The market is, thus, found witnessing a trend that is shifting toward digitalization and patient-centered virtual care. This emphasizes the need for effective real-world solutions.
In April 2020, two healthcare data science companies, Aetion and HealthVerity, were found collaborating, extending their current relationship, to extract real-world medical evidence from electronic health records and advise drug makers and regulators on COVID-19 treatments.
The real-world evidence solutions market will show rapid growth due to the shift from volume to value-based care, increasing aging population and prevalence of chronic diseases, delays in drug development, and subsequent increase in development costs. According to the World Ageing Population report, in 2020 highlights, approximately 727 million people living worldwide were aged 65 years and above, and the number is expected to reach 1.5 billion by 2050. It has been calculated that almost half of the total chronic disease deaths are attributable to cardiovascular diseases, cancer, obesity, and diabetes which are showing increasing trends.
Pharmaceutical companies take several years to introduce a new drug molecule to market, and they invest billions in research and development with a low probability of success. To shorten the drug development cycles, pharma research centers need a clear insight on treatment options that work in a wide population compared to few patient pools in clinical trials. The use of real-world evidence (RWE) insights is thus found to increase as pharma and biotech companies realize that real-world evidence (RWE) can be important in drug development and life-cycle management and increase the innovation efficiency cost of clinical trials.
The big pharmaceutical companies are found using a clinico-genomic database with tumor sequencing information for cancer discovery studies and targeted drug development. Companies are thus able to broaden their indication range and conduct a small number of clinical trials for the rare biomarker-defined population. Thus it indicates the growth of the real-world evidence solutions market during the forecast period.
In addition, the real-world data sets are widely adopted by end users for real-world evidence (RWE) for various applications such as drug development and approvals, market access and reimbursement/coverage decisions, clinical decision-making, and medical device development and approvals, among others, which helps in the growth of the overall market.
Real-World Evidence Solutions Market Trends
Oncology is Anticipated to be the Dominant Segment During the Forecast Period
The oncology segment is expected to hold a significant market share. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide. According to Clinicaltrials.gov, as of February 8, 2022, there are around 87,366 cancer clinical trials across different phases of development.
In August 2020, Syapse and Food and Drug Administration expanded the existing research collaboration to rapidly generate real-world evidence related to COVID-19 and cancer and the use of real-world data (RWD) to support clinical and regulatory decision-making.
Globally, there has been an increased focus on the use of real-world evidence in oncology drugs due to the innovations in immuno-oncology and personalized medicine, fueled by the guidelines of many regulatory authorities, such as the US Food and Drug Administration.
With the increasing use of digital health solutions and experimental cancer therapies, real-world data can support numerous aspects of medical research and routine clinical practice.
Pragmatic trials, which are designed to evaluate the effectiveness of interventions in real life, can combine real-world evidence and information from randomized trials to support the effects of an existing treatment in practice. By including real-world data, oncologists can get involved (especially in the later stages of the study) in helping more patients access novel treatments.
As per the statistics from GLOBOCAN, worldwide, there were around 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) in 2020. This factor, in turn, is expected to boost the demand for real-world evidence (RWE) and can help in defining the therapy and estimate the effectiveness of a therapy in actual clinical practice, reflecting a larger population and longer-term outcomes.
Furthermore, owing to the increased demand for personalized medicine and the complexity of oncology treatment, the collaboration offers an opportunity for the industry to expand the use of real-world evidence (RWE). This factor is expected to drive the segment’s growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market over the Forcast Period
Some of the factors driving the market growth in the North American region include a favorable regulatory environment, a high number of real-world evidence (RWE) service providers, and the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure.
In May 2020, the US Food and Drug Administration and New York-based Aetion collaborated to use real-world data to understand and respond to COVID-19. The collaboration aims to focus on assessing and analyzing real-world data sets to generate information about the course and treatment of the disease, as well as diagnostic patterns, using the company’s Evidence Platform system.
As per the statistics from GLOBOCAN, there were about 2,281,658 cancer cases in the United States in 2020. This number is expected to increase by 2040 and reach 3,096,944 cases. The rising number of cancer cases is creating opportunities for market players. The major market players are focusing on R&D activities to bring new therapies into the market.
Likewise, from drug development to value-based care, there is a huge opportunity to tap into real-world data (RWD) to improve patient outcomes. The information about the function of a medical product is used by patients, and this can help stakeholders in the healthcare ecosystem make important and potentially life-saving real-time decisions.
Moreover, Alberta has one of the largest, most detailed, and comprehensive healthcare data depositories in Canada. Alberta is poised to be a global leader in real-world evidence generation. In order to understand this potential, in May 2021, the Universities of Alberta and Calgary and the Institute of Health Economics led the formation of the Alberta RWE Consortium. Thus, all the aforementioned factors are expected to drive the growth of the market in the North American region during the forecast period.
Real-World Evidence Solutions Market Competitor Analysis
The real-world evidence solutions market is fragmented and competitive. Product launches, partnerships, collaborations, agreements, and market expansions are the key strategies adopted by players to grow and expand their presence in the real-world evidence solutions market. Some of the key players in the market include IQVIA, ICON, PAREXEL, Oracle Corporation, and Clinigen Group.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Shift From Volume- to Value-based Care
4.2.2 Increasing Aging Population and Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 Unwillingness to Rely on Real-world Studies
4.3.2 Lack of Standards
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market SIze by Value – USD Millions)
5.1 By Component
5.1.1 Claims Data
5.1.2 Clinical Settings Data
5.1.3 Patient-Powered Data
5.1.4 Pharmacy Data
5.1.5 Other Components
5.2 By Therapeutic Area
5.2.1 Oncology
5.2.2 Immunology
5.2.3 Neurology
5.2.4 Cardiovascular Disease
5.2.5 Other Therapeutic Areas
5.3 By End User
5.3.1 Healthcare Payers
5.3.2 Healthcare Providers
5.3.3 Pharmaceutical & Medical Device Companies
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinigen Group PLC
6.1.2 Icon PLC
6.1.3 IBM
6.1.4 IQVIA
6.1.5 Oracle Corporation
6.1.6 Parexel International
6.1.7 PerkinElmer Inc.
6.1.8 Pharmaceutical Product Development (PPD Inc.)
6.1.9 SAS Institute
6.1.10 Syneos Health
6.1.11 Flatiron Health Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS